Iron Chelator Deferiprone Restores Iron Homeostasis and Inhibits Retinal Neovascularization in Experimental Neovascular Age-Related Macular Degeneration

Invest Ophthalmol Vis Sci. 2024 Aug 1;65(10):5. doi: 10.1167/iovs.65.10.5.

Abstract

Purpose: Retinal neovascularization is a significant feature of advanced age-related macular degeneration (AMD) and a major cause of blindness in patients with AMD. However, the underlying mechanism of this pathological neovascularization remains unknown. Iron metabolism has been implicated in various biological processes. This study was conducted to investigate the effects of iron metabolism on retinal neovascularization in neovascular AMD (nAMD).

Methods: C57BL/6J and very low-density lipoprotein receptor (VLDLR) knockout (Vldlr-/-) mice, a murine model of nAMD, were used in this study. Bulk-RNA sequencing was used to identify differentially expressed genes. Western blot analysis was performed to test the expression of proteins. Iron chelator deferiprone (DFP) was administrated to the mice by oral gavage. Fundus fluorescein angiography was used to evaluate retinal vascular leakage. Immunofluorescence staining was used to detect macrophages and iron-related proteins.

Results: RNA sequencing (RNA-seq) results showed altered transferrin expression in the retina and RPE of Vldlr-/- mice. Disrupted iron homeostasis was observed in the retina and RPE of Vldlr-/- mice. DFP mitigated iron overload and significantly reduced retinal neovascularization and vascular leakage. In addition, DFP suppressed the inflammation in Vldlr-/- retinas. The reduced signals of macrophages were observed at sites of neovascularization in the retina and RPE of Vldlr-/- mice after DFP treatment. Further, the IL-6/JAK2/STAT3 signaling pathway was activated in the retina and RPE of Vldlr-/- mice and reversed by DFP treatment.

Conclusions: Disrupted iron metabolism may contribute to retinal neovascularization in nAMD. Restoring iron homeostasis by DFP could be a potential therapeutic approach for nAMD.

MeSH terms

  • Animals
  • Blotting, Western
  • Deferiprone* / pharmacology
  • Deferiprone* / therapeutic use
  • Disease Models, Animal*
  • Fluorescein Angiography
  • Homeostasis*
  • Iron Chelating Agents* / pharmacology
  • Iron Chelating Agents* / therapeutic use
  • Iron* / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL*
  • Mice, Knockout*
  • Receptors, LDL / genetics
  • Receptors, LDL / metabolism
  • Retinal Neovascularization* / drug therapy
  • Retinal Neovascularization* / etiology
  • Retinal Neovascularization* / metabolism
  • Retinal Neovascularization* / pathology
  • Retinal Pigment Epithelium / drug effects
  • Retinal Pigment Epithelium / metabolism
  • Retinal Pigment Epithelium / pathology
  • STAT3 Transcription Factor / metabolism
  • Wet Macular Degeneration / drug therapy
  • Wet Macular Degeneration / metabolism

Substances

  • Deferiprone
  • Iron Chelating Agents
  • Iron
  • VLDL receptor
  • Receptors, LDL
  • STAT3 Transcription Factor